Spark Therapeutics Inc. (Nasdaq: ONCE) reported disappointing preliminary results from a Phase 1/2 clinical trial of SPK-8011 to treat hemophilia A sending the stock price plummeting $25.66 to close at $47.72.
Spark Therapeutics reports disappointing results
December 11, 2017 at 17:10 PM EST